Abstract
In this issue of Blood, Seth Chhabra et al describe the engineering of a new therapeutic chimera composed of B domain-deleted (BDD) factor VIII (FVIII), FVIII-binding domain of von Willebrand factor (VWF), Fcg1 fragment, and XTEN polypeptides.1 The molecule, referred to as rFVIIIFc-VWF-XTEN or BIVV001, has a prolonged half-life that is independent from endogenous VWF and is hemostatically competent.
| Original language | English |
|---|---|
| Pages (from-to) | 1417-1419 |
| Number of pages | 3 |
| Journal | Blood |
| Volume | 135 |
| Issue number | 17 |
| DOIs | |
| Publication status | Published - 23 Apr 2020 |
Bibliographical note
Funding Information:Conflict-of-interest disclosure: J.R. declares no competing financial interests. S.L.-D. is the recipient of a research grant from Sanofi Genzyme and Sobi. n
Publisher Copyright:
© 2020 by The American Society of Hematology.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology